X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with ALEMBIC PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ALEMBIC PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ALEMBIC PHARMA DISHMAN PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 25.1 26.3 95.3% View Chart
P/BV x 3.3 6.0 55.7% View Chart
Dividend Yield % 0.7 0.8 84.7%  

Financials

 DISHMAN PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ALEMBIC PHARMA
Mar-16
DISHMAN PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs374792 47.3%   
Low Rs129443 29.1%   
Sales per share (Unadj.) Rs197.8167.0 118.4%  
Earnings per share (Unadj.) Rs21.238.2 55.6%  
Cash flow per share (Unadj.) Rs34.742.0 82.7%  
Dividends per share (Unadj.) Rs2.004.00 50.0%  
Dividend yield (eoy) %0.80.6 122.7%  
Book value per share (Unadj.) Rs179.984.9 211.9%  
Shares outstanding (eoy) m80.69188.52 42.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.7 34.4%   
Avg P/E ratio x11.916.2 73.4%  
P/CF ratio (eoy) x7.214.7 49.3%  
Price / Book Value ratio x1.47.3 19.2%  
Dividend payout %9.410.5 90.0%   
Avg Mkt Cap Rs m20,306116,383 17.4%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3554,214 127.1%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,96131,487 50.7%  
Other income Rs m26555 481.7%   
Total revenues Rs m16,22631,542 51.4%   
Gross profit Rs m4,10310,060 40.8%  
Depreciation Rs m1,091722 151.0%   
Interest Rs m94437 2,566.3%   
Profit before tax Rs m2,3349,356 24.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m1-2 -73.3%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6242,160 28.9%   
Profit after tax Rs m1,7117,194 23.8%  
Gross profit margin %25.731.9 80.5%  
Effective tax rate %26.723.1 115.7%   
Net profit margin %10.722.8 46.9%  
BALANCE SHEET DATA
Current assets Rs m11,01815,066 73.1%   
Current liabilities Rs m9,5177,674 124.0%   
Net working cap to sales %9.423.5 40.1%  
Current ratio x1.22.0 59.0%  
Inventory Days Days11067 165.0%  
Debtors Days Days3541 85.7%  
Net fixed assets Rs m16,3048,237 197.9%   
Share capital Rs m161377 42.8%   
"Free" reserves Rs m12,90715,416 83.7%   
Net worth Rs m14,51616,005 90.7%   
Long term debt Rs m4,1890-   
Total assets Rs m29,80524,594 121.2%  
Interest coverage x3.5255.2 1.4%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.3 41.8%   
Return on assets %8.929.4 30.3%  
Return on equity %11.844.9 26.2%  
Return on capital %17.558.7 29.9%  
Exports to sales %24.855.7 44.5%   
Imports to sales %3.710.4 35.8%   
Exports (fob) Rs m3,95617,551 22.5%   
Imports (cif) Rs m5963,283 18.2%   
Fx inflow Rs m4,95217,811 27.8%   
Fx outflow Rs m6975,318 13.1%   
Net fx Rs m4,25512,493 34.1%   
CASH FLOW
From Operations Rs m2,7869,304 29.9%  
From Investments Rs m-1,529-3,105 49.2%  
From Financial Activity Rs m-941-1,959 48.0%  
Net Cashflow Rs m3164,240 7.5%  

Share Holding

Indian Promoters % 61.4 74.1 82.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 2.9 127.6%  
FIIs % 12.7 9.1 139.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 13.9 159.0%  
Shareholders   46,261 49,328 93.8%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - SUVEN LIFE COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS